CEO Total Pay
$235K
FY2023 Summary Compensation, below median
KPTI FY2023 SEC EDGAR DEF 14A
Karyopharm Therapeutics Inc. CEO pay ratio
The CEO earned $235K in FY2023 against median worker pay of $234,684 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2024-04-19
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2023
Data updated August 2026
Subscribe to Karyopharm Therapeutics Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
11:1
Below Average (Scale: 0–1000:1)
CEO pay
$235K
Median worker
$234,684
Latest filing FY2023. This company's newest DEF 14A on file is for FY2023, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Karyopharm Therapeutics Inc. reported a 11:1 CEO-to-worker pay ratio in FY2023 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 11:1
- FY2023 disclosed
- CEO total
- $235K
- Summary Compensation Table total
- Median worker
- $234,684
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2023
A component-level pay breakdown is not reported in Karyopharm Therapeutics Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Karyopharm Therapeutics Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2023. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 11:1
- FY2023
- vs prior FY
- -20:1
- from FY2022 31:1
- CEO $ YoY
- -97%
- $235K latest
- Filings shown
- 3
- FY2021–2023
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $8.6M | - | $213,593 | 40:1 | - |
| 2022 | $6.9M | -19% | $222,523 | 31:1 | -9:1 |
| 2023 | $235K | -97% | $234,684 | 11:1 | -20:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1503802, FY2021–2023. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
11:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$235K
Companies in Industry
168
vs. Industry Median
Below
Karyopharm Therapeutics Inc.: near-parity Item 402(u) ratio
Karyopharm Therapeutics Inc. stamps FLOOR · ELITE-MED at 11:1 against $234,684 median worker pay in FY2023. the CEO earned 11× the median employee ($234,684) in FY2023.
At $234,684 median worker pay, the FLOOR stamp is near pay-parity territory under MICRO CEO total.
Pay Ratio
11:1
Below typical
What FY2023 shows for Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. stamps FLOOR · ELITE-MED at 11:1 against $234,684 median worker pay in FY2023. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Karyopharm Therapeutics Inc.'s $235K CEO total is at or below the $7.9M industry median CEO pay.
Karyopharm Therapeutics Inc. stamps FLOOR · MICRO · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2023
- Total Compensation
- $235K
- Median Employee Pay
- $234,684
- Pay Ratio
- 11:1
- Filing Date
- 2024-04-19
Company Info
- Ticker
- KPTI
- CIK
- 1503802
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 1503802, FY2023. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Karyopharm Therapeutics Inc. stamps FLOOR · ELITE-MED at 11:1 against $234,684 median worker pay in FY2023.
Read with Karyopharm Therapeutics Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MICRO · ELITE-MED.
Home Bancshares Inc · MICRO
ABS(ceo_total_comp) peer at $232K (Δ $3K lighter vs Karyopharm Therapeutics Inc.); FLOOR · LOW-MED vs this page's FLOOR · MICRO · ELITE-MED.
Confluent, Inc. · MICRO
ABS(ceo_total_comp) peer at $240K (Δ $5K heavier vs Karyopharm Therapeutics Inc.); MODEST · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Adverum Biotechnologies, Inc. · MICRO
ABS(ceo_total_comp) peer at $229K (Δ $5K lighter vs Karyopharm Therapeutics Inc.); FLOOR · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
West Bancorporation Inc · MICRO
ABS(ceo_total_comp) peer at $226K (Δ $8K lighter vs Karyopharm Therapeutics Inc.); FLOOR · HIGH-MED vs this page's FLOOR · MICRO · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Karyopharm Therapeutics Inc. stamps FLOOR · MICRO · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · FLOOR
See where FLOOR · MICRO packages sit on the national leaderboard after reading Karyopharm Therapeutics Inc..
Ratio primer · FLOOR
Karyopharm Therapeutics Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Karyopharm Therapeutics Inc. (CIK 1503802), FY2023. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.